Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 13.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painopioidanalgesicpurposeacute
  Phrases that lowered it: evaluate theto evaluateparticipantseffects ofof age
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 14.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Drug's FAERS reports before start: 657763 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 71.5% (lowers risk) · Drug's FDA history
• Number of arms: 4 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 7 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 97895 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 53 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• CBD for Dental Pain NCT04642404 · started 2021 · scored riskier than 16% of active trials completed
• Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers NCT02751359 · started 2016 · scored riskier than 7% of active trials completed
• A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones NCT04387617 · started 2021 · scored riskier than 73% of active trials completed
• Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain NCT01216163 · started 2010 · scored riskier than 24% of active trials completed
• Reducing Pain and Opioid Use With CBD NCT05299944 · started 2022 · scored riskier than 38% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.